The influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes
- Jaco Voorham, MSc (j.voorham{at}epi.umcg.nl),
- Flora Haaijer-Ruskamp, PhD,
- Petra Denig, PhD,
- Bruce HR Wolffenbuttel, MD, PhD and
- Ronald P Stolk, MD, PhD
- Clinical Pharmacology, University of Groningen, The Netherlands
- Endocrinology, University of Groningen, The Netherlands
- Epidemiology, University of Groningen, The Netherlands
Abstract
Abstract Undertreatment of risk factors in patients with type 2 is common. We assessed the influence of elevated levels of blood pressure, total cholesterol and HbA1c on decisions of Dutch general practitioners to change drug treatment in a cohort of 3029 patients during a 1-year period.
Abstract Respectively 58%, 71% and 21% of patients remained untreated despite poor blood pressure, lipid levels and glycemic control. Of poorly controlled but already drug-treated patients, 52% did not receive intensification for antihypertensive medication, 81% not for lipid-lowering medication, and 43% not for glucose-lowering medication. We observed a significantly lower treatment intervention rate in moderately controlled than in poorly controlled patients for blood pressure. This was not seen for decisions on cholesterol or HbA1c results.
Abstract The low overall action rates observed for blood pressure and especially lipid management cannot sufficiently be explained by the use of higher treatment thresholds than indicated by guidelines.
Footnotes
-
- Received June 1, 2007.
- Accepted December 4, 2007.
- Copyright © American Diabetes Association
